Table 1.
Patient Characteristics at Baseline
| Demographic Characteristics | 2018 Cohort (N = 1792) |
|---|---|
| Age (years), median (IQR) | 57.0 (17.0) |
| Dialysis vintage (months), median (IQR) | 33.9 (52.0) |
| Pre-dialysis body mass index (kg/m2), median (IQR) | 30.4 (10.6) |
| Female, n (%) | 715 (39.9%) |
| Race, n (%)a | |
| White | 911 (50.8%) |
| Black/African American | 756 (42.2%) |
| Other | 70 (3.9%) |
| Unknown | 55 (3.1%) |
| Hispanic/Latino, n (%)a | 266 (14.8%) |
| Primary cause of renal failure, n (%) | |
| Diabetes mellitus | 850 (47.4%) |
| Hypertension | 575 (32.1%) |
| Glomerulonephritis | 123 (6.9%) |
| Polycystic kidney | 42 (2.3%) |
| Other | 201 (11.2%) |
| Unknown | 1 (0.1%) |
| Diabetes mellitus, n (%) | 1035 (57.8%) |
| Congestive heart failure, n (%) | 331 (18.5%) |
| PB at baseline, n (%) | |
| Sevelamer | 841 (46.9%) |
| Calcium acetate | 646 (36.0%) |
| Lanthanum carbonate | 54 (3.0%) |
| Ferric citrate | 115 (6.4%) |
| Switch among bindersb | 136 (7.6%) |
Notes: aRace/ethnicity was self-reported. bAmong 136 patients, the most frequently used phosphate binders were sevelamer (44.9%; n = 61), calcium acetate (37.5%; n = 51), ferric citrate (14.0%; n = 19), and lanthanum carbonate (3.7%; n = 5).
Abbreviations: IQR, interquartile range; PB, phosphate binder.